Policy News

SB 483, SB 484 and SB 485 were introduced in mid-September 2023 that would establish a new state board – a so-called Prescription Drug Affordability Board (PDAB) – that would determine how much pharmaceutical companies can charge for certain drugs by setting an “upper price limit”. According to PDAB supporters, such a body would lower…

Early fall 2023 saw a package of bills introduced that would reestablish a state research & development R&D) tax credit in Michigan – HBs 5099, 5100, 5101 and 5102. Ever since Michigan moved from the Michigan Business Tax regime to the current Corporate Income Tax regime twelve years ago, Michigan taxpayers have not been afforded…

The America Innovation and R&D Competitiveness Act of 2023 or HB 2673 was reintroduced that would repeal current rules and allow a business to deduct of R&D costs in the tax year that they occur and thereby incentivize long-term investments in innovation. Such repeal has been a top policy priority for MichBio and the bio-industry generally…

On December 7, the Biden Administration announced new efforts intended to lower prescription drug costs. While the announcement includes broader initiatives, one component would allow invoking March-In rights under the Bayh-Dole Act to license the patent rights of drugs to other biopharmaceutical manufacturers when the price of the drug is deemed to be too high. MichBio has grave…

The Federal Trade Commission (FTC) and Department of Justice (DOJ) released new merger guidelines that have implications for the life sciences industry. The new guidelines may give regulators more ammunition to go after vertical and cross-market M&A that has historically been more difficult to challenge. Private equity “roll-ups” of multiple companies may also face heightened scrutiny. The…

HB 4409, the “Drug Manufacturer Data Reporting Act” was introduced recently by Rep. Steckloff (D-MI-19), as an attempt to seek more transparency and control of drug prices. The bill would require biotech/pharma companies to provide information on a range of expenses including R&D, marketing, clinical development, whether and how much the company received in federal…

Rep. Jason Morgan (D- MI-23) introduced HB 4167 late February, the latest attempt to establish a Rare Disease Advisory Council (RDAC) in Michigan. A RDAC would empower rare disease patients as partners in helping to shape policy development relevant to the unmet needs, common struggles, and concerns on equitable, quality, and affordable access to specialty…

The House Financial Services Committee, in a marathon session late April, considered a package of 15 bills designed to relieve regulatory burdens and facilitate access to needed capital for biotech startups. Among them were the following: The Equal Opportunity for All Investors Act,which would create a certification exam to qualify as an accredited investor so more…

Reps. Buddy Carter (R-GA) and Carol Miller (R-WV) reintroduced the Manufacturing API, Drugs, and Excipients (MADE) In America Act to prevent U.S. pharmaceutical supply chain dependence on China and other foreign adversaries. The MADE in America Act will stimulate domestic manufacturing of drugs and pharmaceutical supplies such as active pharmaceutical ingredients (API) and personal protective…

The Senate HELP Committee is taking up four bills – S 1607 (Ensuring Timely Access to Generics Act of 2023), S 1214 (Retaining Access and Restoring Exclusivity Act of 2023), S 1114 (Expanding Access to Low-Cost Generics Act of 2023), and S 1339 (Pharmacy Benefit Manager Reform Act) – introduced with a focus on regulating drug…